BioCentury
ARTICLE | Company News

Amgen, VGNX in pharmacogenomics deal

January 4, 2001 8:00 AM UTC

Variagenics (VGNX) will use its Variagenic Impact Program (VIP) to develop assays for an undisclosed therapeutic for AMGN. VIP uses bioinformatics software and experiments to measure haplotypes that c...